Dupilumab
HUM00227361
Approved small_molecule completed
Quick answer
Dupilumab for Dermal Hypersensitivity Reaction is a Approved program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Dermal Hypersensitivity Reaction
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed